Updates to Microhematuria: AUA/SUFU Guideline (2025).

IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY
Journal of Urology Pub Date : 2025-05-01 Epub Date: 2025-02-27 DOI:10.1097/JU.0000000000004490
Daniel A Barocas, Yair Lotan, Richard S Matulewicz, Jay D Raman, Mary E Westerman, Erin Kirkby, Lauren J Pak, Lesley Souter
{"title":"Updates to Microhematuria: AUA/SUFU Guideline (2025).","authors":"Daniel A Barocas, Yair Lotan, Richard S Matulewicz, Jay D Raman, Mary E Westerman, Erin Kirkby, Lauren J Pak, Lesley Souter","doi":"10.1097/JU.0000000000004490","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>In 2023 the AUA in collaboration with the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) requested an Update Literature Review to incorporate new evidence generated since the 2020 publication of this Guideline. The resulting 2025 Microhematuria Guideline Amendment addresses updated recommendations to provide a clinical framework for the diagnosis, evaluation, and follow-up of microhematuria.</p><p><strong>Materials and methods: </strong>In 2024, this Guideline was reviewed via the AUA Update Literature Review process, which identified 82 studies for full-text review that were published between December 2019 and June 7, 2024. Of those 82 studies, 23 met inclusion criteria for qualitative synthesis. The subsequent amendment is based on data released since the initial 2020 publication of this Guideline.</p><p><strong>Results: </strong>The Panel developed evidence- and consensus-based statements based on an updated review to provide guidance on evaluation and management of microhematuria. These updates are detailed herein.</p><p><strong>Conclusions: </strong>This update provides several new insights, including a revised risk stratification system, updated information regarding use of urine-based tumor markers and cytology, and new guidance on diagnosis and surveillance. This Guideline will require further review as the diagnostic and treatment options in this space continue to evolve.</p>","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"547-557"},"PeriodicalIF":5.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JU.0000000000004490","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: In 2023 the AUA in collaboration with the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) requested an Update Literature Review to incorporate new evidence generated since the 2020 publication of this Guideline. The resulting 2025 Microhematuria Guideline Amendment addresses updated recommendations to provide a clinical framework for the diagnosis, evaluation, and follow-up of microhematuria.

Materials and methods: In 2024, this Guideline was reviewed via the AUA Update Literature Review process, which identified 82 studies for full-text review that were published between December 2019 and June 7, 2024. Of those 82 studies, 23 met inclusion criteria for qualitative synthesis. The subsequent amendment is based on data released since the initial 2020 publication of this Guideline.

Results: The Panel developed evidence- and consensus-based statements based on an updated review to provide guidance on evaluation and management of microhematuria. These updates are detailed herein.

Conclusions: This update provides several new insights, including a revised risk stratification system, updated information regarding use of urine-based tumor markers and cytology, and new guidance on diagnosis and surveillance. This Guideline will require further review as the diagnostic and treatment options in this space continue to evolve.

微量血尿的更新:AUA/SUFU指南(2025)。
目的:2023年,美国泌尿学会(AUA)与泌尿动力学、女性盆腔医学和泌尿生殖器官重建学会(SUFU)合作,要求进行一项最新文献综述(ULR),以纳入自2020年本指南发布以来产生的新证据。由此产生的2025指南修正案提出了更新的建议,为微血尿(MH)的诊断、评估和随访提供了临床框架。材料和方法:2024年,通过AUA ULR流程对本指南进行了审查,该流程确定了2019年12月至2024年6月7日期间发表的82项研究进行全文审查。在这82项研究中,有23项符合定性综合的纳入标准。随后的修订基于自2020年本指南首次发布以来发布的数据。结果:专家组根据更新的综述制定了基于证据和共识的声明,为MH的评估和管理提供指导。本文详细介绍了这些更新。结论:该更新提供了一些新的见解,包括修订的风险分层系统,关于使用基于尿液的肿瘤标志物和细胞学的最新信息,以及关于诊断和监测的新指南。随着这一领域诊断和治疗方案的不断发展,本指南将需要进一步审查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Urology
Journal of Urology 医学-泌尿学与肾脏学
CiteScore
11.50
自引率
7.60%
发文量
3746
审稿时长
2-3 weeks
期刊介绍: The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide, and practice-oriented reports on significant clinical observations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信